ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0291

Bufalin Alleviates Renal Tubulointerstitial Fibrosis in Diabetic Kidney Disease by Inhibiting STAT3-Mediated Ferroptosis

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Authors

  • Qiao, Yunyang, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
  • Zhang, Aiqing, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Background

The pathological hallmark of diabetic kidney disease (DKD) is tubulointerstitial fibrosis (TIF), which arises from epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) synthesis in renal tubular epithelial cells (RTECs). Bufalin exhibits potential for delaying the progression of kidney disease; however, its precise role and underlying mechanisms remain to be elucidated. Ferroptosis is likely involved in the regulatory progression of bufalin.

Methods

db/db mice and high glucose (HG) -induced RTECs were used as DKD models. Ferrostatin-1 (Fer-1) was further used to inhibit ferroptosis to assess its effect on TIF. Regarding the mechanism, molecular docking was employed to simulate the binding interaction between bufalin and signal transducer and activator of transcription 3 (STAT3). Additionally, the influence of bufalin on the stability of STAT3 mRNA was assessed in the presence of streptomyces D intervention.

Results

Our findings revealed that the treatment of bufalin altered the expression of TIF-related indicators. During the progression of TIF, ferroptosis was activated, characterized by iron overload, elevated lipid peroxidation product generation, and mitochondrial alterations induced by HG. Conversely, Fer-1 reversed these changes and further mitigated TIF. Notably, bufalin exhibited an inhibitory effect on ferroptosis, suggesting a mechanism analogous to Fer-1. Network pharmacology analysis identified STAT3 as a target of bufalin, and knockdown of STAT3 altered the expression of ferroptosis and TIF-related markers. Molecular docking and STAT3 mRNA stability analysis further elucidated the mechanism by which bufalin regulates ferroptosis and TIF.

Conclusion

Bufalin inhibited ferroptosis by decreasing the stability of STAT3 mRNA and further alleviates TIF in DKD.

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)